Cellectis (NASDAQ:CLLS – Get Free Report) announced its earnings results on Thursday. Cellectis Stock PerformanceShares of NASDAQ:CLLS traded up $0.15 during midday trading on Friday, hitting $2.84. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Acadian Asset Management LLC lifted its position in Cellectis by 132.9% during the first quarter. Cellectis Company Profile(Get Free Report)Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology.